John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.
The second half of the year is getting underway. Now, three of our leading experts will share their best stock picks for the remainder of 2026. Get actionable ideas in sectors like tech, biotech, materials, industrials, and more -- and put them to work in your portfolio right away!